Magnasense AB (STO:MAGNA)
Sweden · Delayed Price · Currency is SEK 0.0070
-0.0030 (-30.00%)
At close: Jul 17, 2025
Magnasense AB Company Description
Magnasense AB develops and commercializes diagnostic tests for monitoring and optimizing the dosage of biological drugs.
The company develops a testing platform for oral health, therapeutic drug monitoring, and infectious diseases.
It develops Veritope technology used to optimize the dosage of biological drugs to patients; and the MagniaReader platform.
The company was formerly known as AegirBio AB (publ) and changed its name to Magnasense AB in July 2024.
Magnasense AB was incorporated in 2019 and is based in Lund, Sweden.
Magnasense AB
| Country | Sweden |
| Founded | 2019 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Marco Witteveen |
Contact Details
Address: ScheelevAegen 27 Lund, 223 63 Sweden | |
| Phone | 46 4 62 86 54 00 |
| Website | magnasense.com |
Stock Details
| Ticker Symbol | MAGNA |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Marco Witteveen | Chief Executive Officer and Director |
| Vicki Johnson | Interim Chief Financial Officer |
| Dr. Vasiliki Fragkou | Chief Operating Officer |